First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
type: MedicalStudy
description: A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Gynaecological Cancers
status: ACTIVE_NOT_RECRUITING
study design: INTERVENTIONAL
phase: PHASE1
start date: 2023-01-11
end date: 2027-02
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05527184
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: AbbVie
study subject: Endometrial Cancer
study subject: High Grade Serous Adenocarcinoma of Ovary
study subject: Primary Peritoneal Carcinoma
study subject: Fallopian Tube Cancer
study subject: Cervical Cancer
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: ACTIVE_NOT_RECRUITING
keywords: Endometrial Cancer
keywords: High Grade Serous Adenocarcinoma of Ovary
keywords: Primary Peritoneal Carcinoma
keywords: Fallopian Tube Cancer
keywords: Cervical Cancer

AI Analytics
type: Organization